Switch theme
Sign up to access all valuation multiples
AmorePacific Corp is a Korean beauty, household, and healthcare goods producer. The product categories are moisturizer, eye care, serum and ampoule, cushion and coverage, cleanser, toner and fluid, masque, sun care, and special care. Its most well-known brands are AmorePacific, Sulwhasoo, Laneige, and Etude House. Most of the firm's revenue is generated in Korea, followed by China, Europe, and North America. The company has research centers not only in Korea, but also internationally in countries such as France, Japan, and China.
2006
n/a
LTM Revenue $3.0B
LTM EBITDA $407M
$5.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AmorePacific has a last 12-month revenue (LTM) of $3.0B and a last 12-month EBITDA of $407M.
In the most recent fiscal year, AmorePacific achieved revenue of $2.8B and an EBITDA of $659M.
AmorePacific expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AmorePacific valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | XXX | $2.8B | XXX | XXX | XXX |
| Gross Profit | $2.1B | XXX | $2.0B | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 71% | XXX | XXX | XXX |
| EBITDA | $407M | XXX | $659M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 23% | XXX | XXX | XXX |
| EBIT | $219M | XXX | $160M | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 6% | XXX | XXX | XXX |
| Net Profit | $355M | XXX | $431M | XXX | XXX | XXX |
| Net Margin | 12% | XXX | 15% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AmorePacific's stock price is KRW 119994 (or $87).
AmorePacific has current market cap of KRW 8.28T (or $6.0B), and EV of KRW 7.76T (or $5.6B).
See AmorePacific trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.6B | $6.0B | XXX | XXX | XXX | XXX | $5.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AmorePacific has market cap of $6.0B and EV of $5.6B.
AmorePacific's trades at 2.0x EV/Revenue multiple, and 8.6x EV/EBITDA.
Equity research analysts estimate AmorePacific's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AmorePacific has a P/E ratio of 17.0x.
See valuation multiples for AmorePacific and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.0B | XXX | $6.0B | XXX | XXX | XXX |
| EV (current) | $5.6B | XXX | $5.6B | XXX | XXX | XXX |
| EV/Revenue | 1.9x | XXX | 2.0x | XXX | XXX | XXX |
| EV/EBITDA | 13.9x | XXX | 8.6x | XXX | XXX | XXX |
| EV/EBIT | 25.7x | XXX | 35.2x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.0x | XXX | 14.0x | XXX | XXX | XXX |
| EV/FCF | 20.8x | XXX | 33.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAmorePacific's last 12 month revenue growth is 10%
AmorePacific's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
AmorePacific's rule of 40 is 25% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AmorePacific's rule of X is 40% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AmorePacific and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 23% | XXX | XXX | XXX |
| EBITDA Growth | 25% | XXX | 11% | XXX | XXX | XXX |
| Rule of 40 | 25% | XXX | 34% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 65% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AmorePacific acquired XXX companies to date.
Last acquisition by AmorePacific was XXXXXXXX, XXXXX XXXXX XXXXXX . AmorePacific acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AmorePacific founded? | AmorePacific was founded in 2006. |
| Where is AmorePacific headquartered? | AmorePacific is headquartered in South Korea. |
| Who is the CEO of AmorePacific? | AmorePacific's CEO is Mr. Kyung-Bae Seo. |
| Is AmorePacific publicy listed? | Yes, AmorePacific is a public company listed on KRX. |
| What is the stock symbol of AmorePacific? | AmorePacific trades under 090430 ticker. |
| When did AmorePacific go public? | AmorePacific went public in 2006. |
| Who are competitors of AmorePacific? | Similar companies to AmorePacific include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of AmorePacific? | AmorePacific's current market cap is $6.0B |
| What is the current revenue of AmorePacific? | AmorePacific's last 12 months revenue is $3.0B. |
| What is the current revenue growth of AmorePacific? | AmorePacific revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of AmorePacific? | Current revenue multiple of AmorePacific is 1.9x. |
| Is AmorePacific profitable? | Yes, AmorePacific is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AmorePacific? | AmorePacific's last 12 months EBITDA is $407M. |
| What is AmorePacific's EBITDA margin? | AmorePacific's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of AmorePacific? | Current EBITDA multiple of AmorePacific is 13.9x. |
| What is the current FCF of AmorePacific? | AmorePacific's last 12 months FCF is $271M. |
| What is AmorePacific's FCF margin? | AmorePacific's last 12 months FCF margin is 9%. |
| What is the current EV/FCF multiple of AmorePacific? | Current FCF multiple of AmorePacific is 20.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
